IPO
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation
Sareum Holdings plc, the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.
Sensyne Health plc, the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors.
Sensyne Health plc, the British Clinical AI technology company, announces its audited full year results for the 12 months ended 30 April 2019.
The Board of Directors of Promore Pharma AB has resolved to carry out a new share issue with preferential rights for the Company’s existing shareholders of a total of SEK 75 million excluding transaction costs.
New myTXTL bulk packagings align with volumes required for high-throughput organizations in synthetic biology.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.
PRESS RELEASES